[HTML][HTML] Low immunogenicity of tocilizumab in patients with rheumatoid arthritis

…, W Reiss, A Pethoe-Schramm, NL Mallalieu… - Annals of the …, 2017 - ard.bmj.com
Objective Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are
available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and …

Safety and pharmacokinetic characterization of nacubactam, a novel β-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers

NL Mallalieu, E Winter, S Fettner, K Patel… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Nacubactam is a novel β-lactamase inhibitor with dual mechanisms of action as an inhibitor
of serine β-lactamases (classes A and C and some class D) and an inhibitor of penicillin …

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

…, K Bharucha, W Douglass, M Bao, NL Mallalieu… - …, 2021 - academic.oup.com
Objectives To determine sc tocilizumab (sc-TCZ) dosing regimens for systemic JIA (sJIA)
and polyarticular JIA (pJIA). Methods In two 52-week phase 1 b trials, sc-TCZ (162 mg/dose) …

Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector

…, C Wells, W Douglass, NL Mallalieu - Expert Opinion on …, 2019 - Taylor & Francis
Background: The anti–interleukin-6 receptor antibody tocilizumab is approved for subcutaneous
injection using a prefilled syringe (PFS). We report results from a bioequivalence study …

[HTML][HTML] Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 …

NL Mallalieu, S Wimalasundera, JC Hsu… - Pediatric …, 2019 - Springer
Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for
intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (…

A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and …

…, M Zell, C Funk, T Hartung, A Gloge, NL Mallalieu - Xenobiotica, 2017 - Taylor & Francis
The emerging technique of employing intravenous microdose administration of an isotope
tracer concomitantly with an [ 14 C]-labeled oral dose was used to characterize the disposition …

Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes

…, NR Scott, J Grimsby, NL Mallalieu - ACS Medicinal …, 2013 - ACS Publications
To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we
carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic …

Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor

NL Mallalieu, MH Rahimy, CA Crowley… - Clinical …, 2014 - Elsevier
NL Mallalieu owns shares in Hoffmann-La Roche; CA Crowley was a former employee of
Anadys, but does not currently hold any financial interest in either Anadys or Roche; and PF …

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized

…, Y Cleary, N Parrott, G Greig, NL Mallalieu - … of Pharmacology and …, 2017 - ASPET
… Wrote or contributed to the writing of the manuscript: Fowler, Mallalieu … Guerini E, Schadt
S, Greig G, Haas R, Husser C, Zell M, Funk C, Hartung T, Gloge A and Mallalieu NL (2016) A …

Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem

NL Mallalieu, S Lennon, M Liu… - Antimicrobial agents …, 2008 - Am Soc Microbiol
The objective of this study was to assess the impact of impaired renal function on the
pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem antibiotic, and its …